Pyxis Oncology (NASDAQ:PYXS) Rating Lowered to “Market Perform” at William Blair

Pyxis Oncology (NASDAQ:PYXS) was downgraded by equities research analysts at William Blair from an “outperform” rating to a “market perform” rating in a research note issued on Thursday, MarketBeat reports.

Several other equities analysts have also recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Pyxis Oncology in a report on Friday, August 16th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $7.00 target price on shares of Pyxis Oncology in a research note on Thursday, September 19th. Stephens initiated coverage on shares of Pyxis Oncology in a research note on Friday, November 8th. They set an “overweight” rating and a $13.00 price target for the company. Finally, Stifel Nicolaus initiated coverage on shares of Pyxis Oncology in a research note on Thursday, August 8th. They issued a “buy” rating and a $10.00 price objective on the stock. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Pyxis Oncology Stock Performance

NASDAQ:PYXS opened at $1.90 on Thursday. The company has a market cap of $112.99 million, a price-to-earnings ratio of -1.84 and a beta of 1.27. The stock’s fifty day moving average price is $3.64 and its two-hundred day moving average price is $3.62. Pyxis Oncology has a 52-week low of $1.35 and a 52-week high of $6.85.

Institutional Investors Weigh In On Pyxis Oncology

Hedge funds have recently bought and sold shares of the company. Ikarian Capital LLC bought a new stake in shares of Pyxis Oncology in the 1st quarter valued at $7,082,000. Blue Owl Capital Holdings LP acquired a new position in Pyxis Oncology in the second quarter valued at about $3,462,000. Millennium Management LLC increased its holdings in shares of Pyxis Oncology by 125.3% in the second quarter. Millennium Management LLC now owns 1,336,908 shares of the company’s stock worth $4,425,000 after acquiring an additional 743,499 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Pyxis Oncology during the third quarter worth about $1,405,000. Finally, State Street Corp lifted its holdings in shares of Pyxis Oncology by 28.0% during the 3rd quarter. State Street Corp now owns 951,251 shares of the company’s stock valued at $3,491,000 after purchasing an additional 208,344 shares in the last quarter. 39.09% of the stock is currently owned by institutional investors and hedge funds.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.